Additional efforts targeting gamma-secretase for AD therapy have been influenced by gamma-secretase cleavage site modulating properties of certain NSAIDS [43-45], and APP substrate selective/Notch sparing GSIs (this report, [46-48]) as a means toward mitigating inhibition of Notch signaling. Here, APP is linked to Alzheimer disease.